Showing 7051-7060 of 9095 results for "".
- Study Quantifies Cutaneous Reaction Risks of Some CKD Treatmentshttps://practicaldermatology.com/news/study-quantifies-cutaneous-reaction-risks-of-some-ckd-treatments/2483518/A newly validated risk prediction model in The Lancet Rheumatology could assist practitioners in estimating a patient’s short-term risk of developing severe cutaneous adverse reactions (SCARs) following initiation of allopuri
- Study: Nicotinamide Linked with Reduced Skin Cancer Risk Following First Diagnosishttps://practicaldermatology.com/news/va-study-finds-nicotinamide-reduces-skin-cancer-risk-after-first-diagnosis/2483481/A large Veterans Affairs (VA) cohort study has found that nicotinamide supplementation is associated with a reduced risk of subsequent skin cancers, particularly when initiated after a patient’s first diagnosis. Researchers on t
- From EADV: Povorcitinib Maintains Efficacy Through 24 Weeks in STOP-HS Programhttps://practicaldermatology.com/news/from-eadv-povorcitinib-maintains-efficacy-through-24-weeks-in-hs-phase-3-data/2483429/New 24-week results from the phase 3 STOP-HS trial program suggest that investigational oral JAK1 inhibitor povorcitinib provided sustained clinical benefits in adults with moderate to severe hidradenitis suppurativa (HS), according to findings presented at the 2025
- From EADV: Bimekizumab Shows Sustained Efficacy in Plaque Psoriasis and HShttps://practicaldermatology.com/news/from-eadv-bimekizumab-shows-sustained-efficacy-in-plaque-psoriasis-and-hs/2483464/New data presented by UCB at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris showed sustained efficacy and tolerability for BIMZELX® (bimekizumab-bkzx) in both moderate-to-severe hidradenitis suppurativa (HS) and plaque psoriasis. <
- Galderma to Present Long-Term Nemluvio Data, Global Sensitive Skin Survey at EADV 2025https://practicaldermatology.com/news/galderma-to-present-long-term-nemluvio-data-global-sensitive-skin-survey-at-eadv-2025/2483331/Galderma will present new findings on sensitive skin, as well as long-term data on nemolizumab (Nemluvio®) at the 34th European Academy of Dermatology and Venereology (EADV) Congress, to be held in Paris, September 17–20, 2025, a press statement from the manufactur
- Incyte to Present STOP-HS, TRuE-PN Trials at EADV 2025https://practicaldermatology.com/news/late-breaking-hs-and-pn-data-to-anchor-incytes-eadv-presentations/2483330/Incyte announced that it will present new data from studies throughouts its dermatology pipeline at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, according to a press release from the manufacturer.
- Low Recurrence Observed in MIS Cases With Clear Biopsy Marginshttps://practicaldermatology.com/news/low-recurrence-observed-in-mis-cases-with-clear-biopsy-margins/2483319/A new retrospective cohort study suggests that diagnostic excisional biopsy alone maya be efficacious for select cases of melanoma in situ (MIS) that are neither lentigo maligna (LM) nor acral lentiginous melanoma (ALM) subtypes.
- Psoriasis Patients Show Significant Link to Metabolic Syndrome in Indian Studyhttps://practicaldermatology.com/news/psoriasis-patients-show-significant-link-to-metabolic-syndrome-in-indian-study/2483264/A hospital-based cross-sectional study from India has found that patients with chronic plaque psoriasis show a significant association with metabolic syndrome, highlighting the importance of routine metabolic screening in dermatology practice. Published in <
- NB-UVB Phototherapy Effective for Psoriasis in Skin of Colorhttps://practicaldermatology.com/news/nb-uvb-phototherapy-effective-for-psoriasis-in-skin-of-color/2483263/A new systematic review and meta-analysis confirms that narrowband ultraviolet B (NB-UVB) phototherapy is effective for psoriasis in patients with skin of color, underscoring its role as a valuable treatment option despite the widespread adoption of biologics and systemic agents.
- HS TRUTHS Video Series Centers Patient Experiencehttps://practicaldermatology.com/news/hs-truths-video-series-centers-patient-experience/2483232/Incyte announced this week that it has launched HS TRUTHS, a new disease education initiative aiming to elevate awareness of the lived experiences of individuals with hidradenitis suppurativa (HS).